sciencedaily - Researchers created an AI-driven liquid biopsy that scans patterns in fragments of DNA circulating in the blood. The system detected early liver fibrosis and cirrhosis—conditions that often go unnoticed until serious damage occurs. By analyzing genome-wid…
AI Summary: Researchers unveiled an AI‑driven liquid biopsy that scans genome‑wide cell‑free DNA fragment patterns to flag liver fibrosis, cirrhosis and chronic liver disease well before symptoms appear. Early results indicate the test can identify disease signals years ahead of clinical diagnosis, offering a shot at much earlier intervention — if practice and payers cooperate.
Smartphone app improves premature ejaculation outcomes in randomized trial / 2 months
DeepRare AI beats clinicians at diagnosing rare diseases / 3 months
Grail’s Galleri blood test misses UK study goal; investor jitters / 3 months
FDA clears wearable electric-field therapy for pancreatic cancer patients / 3 months
Researchers grow liver tissue in patients' bodies; study now under scrutiny / 6 wks
CMS proposes mandatory bundled model for joint replacements nationwide / 7 wks
Privacy advocates sue CMS over Medicare AI prior-authorization pilot / 1 month
StackHealth RSS

StackHealth Time Machine
NorthFeed Inc. Terms and Conditions / Privacy Policy
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.